Changes in NK cells. PBMCs obtained from patients before staring therapy (PreC1), before cycle 2 (PreC2), and before cycle 3 (PreC3) as well as day 7 and 14 of each cycle were analyzed for the presence of CD3⁻, CD56⁺ NK cells using flow cytometry. Changes in surface expression of CD56, NCRp46, as well as NKG2D on the surface of the CD3⁻, CD56⁺ NK cells were also monitored by flow cytometry. (A) Summary of pooled data for frequency of circulating NK cells during therapy, reflected as fold change on day 7 and 14 compared with baseline; *P < .05. (B) Representative data from a single patient. (C) Changes in expression of CD56 on NK cells during cycle 1. (Left panel) Data from a representative patient. (Right panel) Summary of pooled data from all patients; P < .05. (D) Changes in expression of NKG2D on NK cells during cycle 1. (Left panel) Data from a representative patient. (Right panel) Summary of pooled data from all patients; ** P = .07. (E) Changes in expression of NCRp46 on NK cells during cycle 1. (Left panel) Data from a representative patient. (Right panel) Summary of pooled data from all patients.